top of page
Open Site Navigation

Phase 2 rGBM

(SDT-202)

SonALAsense is now recruiting for a 50 subject, 3-part Phase 2 trial in recurrent glioblastoma.

Phase 2 rGBM Clinical Trial Design

Part 1 will be an initial drug dose + focused ultrasound energy escalation phase, where patients will be treated with two dose levels of SONALA-001 in combination with one of three dose levels of focused ultrasound as a single dose of SDT.

Part 2 is a schedule escalation phase where 6 patients will be treated twice with SDT. Then 6 patients will be treated three times at the recommended dose from part 1.

Part 3 will be an expansion cohort, where patients will be treated at the recommended SDT dose from part 1 and the recommended SDT schedule from part 2.

For more details visit our ClinicalTrials.gov listing: https://www.clinicaltrials.gov/ct2/show/NCT05370508

This trial is now recruiting, Contact Us to learn more about eligibility.

bottom of page